Apoptosis Incidence and Protein Expression of p53, TGF-β Receptor II, p27Kip1, and Smad4 in Benign, Premalignant, and Malignant Human Prostate

Human Pathology

Volumn 35, Issue 3, 2004, Pages 290-297

  Zeng, Li ^b   Rowland, Randall G ^b   Lele, Subodh M ^b   Kyprianou, Natasha ^a  

^a UNIVERSITY OF KENTUCKY MEDICAL CENTER   (United States)

^b NONE

Author keywords

Apoptosis; High grade prostatic intraepithelial neoplasia; p27Kip1; p53; Prostate carcinoma; Prostate growth; Smad4; Transforming growth factor signaling

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; PROTEIN P27; PROTEIN P53; REGULATOR PROTEIN; SMAD4 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 2; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; AGED; APOPTOSIS; ARTICLE; CANCER CELL; CANCER GROWTH; CANCER LOCALIZATION; CARCINOGENESIS; CARCINOMA IN SITU; CELL ASSAY; CELL POPULATION; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; EPITHELIUM CELL; EVALUATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MALE; NICK END LABELING; PARAMETER; PRECANCER; PROGNOSIS; PROSTATE CANCER; PROSTATECTOMY; PROTEIN EXPRESSION; RECEPTOR DOWN REGULATION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; TISSUE SECTION;

EID: 1542720308     PISSN: 00468177     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.humpath.2003.11.001     Document Type: Article

References (50)

1. Weir HK, Thun MJ, Hankey BF, et al: Annual report to the nation on the status of cancer, 1975-2000, featuring the uses of surveillance data for cancer prevention and control. J Natl Cancer Inst 95:1276-1299, 1975
2. Bruckheimer EB, Kyprianou N: Apoptosis in prostate carcinogenesis: A growth regulator and a therapeutic target. Cell Tissue Res 301:152-162, 2000
3. Berges RR, Vucanovic J, Epstein JI, et al: Implication of cell kinetic changes during the progression of human prostatic cancer. Clin Cancer Res 1:473-480, 1995
4. Tu H, Jacobs SC, Borkowski A, et al: Incidence of apoptosis and cell proliferation in prostate cancer: Relationship with TGF-β and bcl-2 expression. Int J Cancer 69:357-363, 1996
5. Bostwick DG: High-grade prostatic intraepithelial neoplasia. Cancer 75:1823-1836, 1995
6. Sakr WA, Grignon DJ, Haas GP, et al: Age and racial distribution of prostatic intraepithelial neoplasia. Eur Urol 30:138-144, 1996
7. Sakr WA, Partin AW: Histological markers of risk and role of high-grade prostatic intraepithelial neoplasia. Urology 57:115-120, 2001
8. Malkin D, Li FP, Strong LC, et al: Germ line p53 mutations in a familial syndrome of breast cancer sarcomas and other neoplasms. Science 250:1233-1238, 1990
9. Hollstein M, Sidransky D, Vogelstein B, et al: P53 mutations in human cancers. Science 253:492-495, 1991
10. Bauer JJ, Sesterhenn IA, Mostofi FK, et al: p53 nuclear protein expression is an independent prognostic marker in clinically localized prostate cancer patients undergoing radical prostatectomy. Clin Cancer Res 1:1295-1300, 1995
11. Krupsky T, Petroni GR, Frienson HF, et al: Microvessel density, p53, retinoblastoma, and chromogranin A immunohistochemistry as predictors of disease-specific survival following radical prostatectomy for carcinoma of the prostate. Urology 55:743-749, 2000
12. Effert PJ, McCoy RH, Walther PJ, et al: p53 gene alterations in human prostate carcinoma. J Urol 150:257-261, 1992
13. Borner MM, Myers CE, Sartor O, et al: Drug-induced apoptosis is not necessarily dependent on macromolecular synthesis of proliferation in the p53-negative human prostate cell line PC3. Cancer Res 55:2122-2128, 1995
14. Strickler HJ, Jay JK, Linder MD, et al: Determining prognosis of clinically localized prostate cancer by immunohistochemical detection of mutant p53. Urology 47:366-369, 1996
15. Kuczyk MA, Serth J, Bokemeyer C, et al: The prognostic value of p53 for long-term and recurrence-free survival following radical prostatectomy. Eur J Cancer 34:679-686, 1998
16. Stapleton AMF, Zbell P, Kattan MW, et al: Assessment of the biological markers p53, Ki-67, and apoptotic index as predictive indicators of prostate carcinoma recurrence after surgery. Cancer 82:168-175, 1998
17. Sherr CJ: G1 phase progression: Cycling on cue. Cell 79:551-555, 1994
18. Johnson MI, Hamdy FC: Apoptosis-regulating genes in prostate cancer. Oncol Rep 5:553-557, 1998
19. Kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell 78:59-66, 1994
20. Kip1 protein in human prostate cancer correlates with tumor grade. Clin Cancer Res 3:2269-2274, 1997
21. Kip1: A multifunctional cyclin-dependent kinase inhibitor with prognostic significance in human cancers. Am J Pathol 154:313-323, 1999
22. Kip1 levels with recurrence and survival in patients with stage C prostate carcinoma. J Natl Cancer Inst 90:916-920, 1998
23. Kip1 in normal, hyperlastic and neoplastic cells. Am J Pathol 153:911-919, 1998
24. Guo Y, Kyprianou N: Restoration of transforming growth factor beta signaling pathway in human prostate cancer suppresses tumorigenicity via induction of caspase-1-mediated apoptosis. Cancer Res 15:1366-1371, 1999
25. Cardillo MR, Petrangeli E, Perracchio L, et al: Transforming growth factor-β expression in prostate neoplasia. Anal Quant Cytol Histol 22:1-10, 2000
26. Wrana J, Attisano L, Wiesert R, et al: Mechanism of activation of the TGF-β receptor. Nature 370:341-347, 1994
27. Attisano L, Wrana JL: Smads as transcriptional co-modulators. Curr Opin Cell Biol 12:235-243, 2000
28. Massague J, Wotton D: Transcriptional control by the TGF-β/Smad signaling system. EMBO J 19:1745-1754, 2000
29. Markowitz S, Wang J, Myeroff L: Inactivation of the type II TGF-β receptor in colon cancer cells with microstatellite instability. Science 268:1336-1338, 1995
30. Myeroff LL, Parsons R, Kim SJ: A transforming growth factor β receptor type II gene mutation common in colon and gastric but rare in endometrial cancers with microsatellite instability. Cancer Res 55:5545-5547, 1995
31. Grady WM, Myeroff LL, Swinler SE: Mutational inactivation of transforming growth factor β receptor type II in microsatellite-stable colon cancers. Cancer Res 59:320-324, 1999
32. Williams RH, Stapleton AM, Yang G, et al: Reduced levels of transforming growth factor beta receptor type II in human prostate cancer: An immunohistochemical study. Clin Cancer Res 2:635-640, 1996
33. Guo Y, Jacobs SC, Kyprianou N: Down-regulation of protein and mRNA expression for transforming growth factor-β (TGF-β) type I and type II receptors in human prostate cancer. Int J Cancer 71:573-579, 1997
34. Kim IY, Ahn HJ, Zelner DJ, et al: Loss of expression of transforming growth factor-β receptors is associated with poor prognosis in prostate cancer patients. Clin Cancer Res 4:1625-1630, 1998
35. Gold LI: The role for transforming growth factor-β (TGF-β) in human cancer. Crit Rev Oncol 10:303-360, 1999
36. Blobe GC, Schiemann WP, Lobish HF: Role of transforming growth factor β in human disease. N Engl J Med 342:1350-1358, 2000
37. Heldin CH, Miyazono K, ten Dijke P: TGF-β signaling from cell membrane to nucleus through SMAD proteins. Nature 390:465-471, 1997
38. Eppert K, Scherer SW, Ozcelik H, et al: MADR2 maps to 18q21 and encodes a TGF-β-regulated, MAD-regulated protein that is functionally mutated in colorectal carcinoma. Cell 86:543-552, 1996
39. Brodin G, ten Dijke PT, Funa K, et al: Increased Smad expression and activation are associated with apoptosis in normal and malignant prostate after castration. Cancer Res 59:2731-2738, 1999
40. Gatalica Z, Lele SM, Rampy BA, et al: The expression of FHIT protein is related inversely to disease progression in patients with breast carcinoma. Cancer 88:1378-1383, 2000
41. Djakiew D: Deregulated expression of growth factors and their receptors in the development of prostate cancer. Prostate 38: 268-277, 2000
42. Kip1 gene expression in benign prostatic hyperplasia and prostatic carcinoma. J Natl Cancer Inst 90:1284-1291, 1998
43. Loda M, Cukor B, Tam SW, et al: Increased proteasome-dependent degradation of cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas. Nat Med 3:231-234, 1997
44. Carrano AC, Eytan E, Hershko A, et al: SKP2 is required for ubiquitin-mediated degradation of the CDK inhibitor p27. Nat Cell Biol 1:193-199, 1999
45. Shim E-H, Johnson L, Noh H-L, et al: Expression of the F-box protein SKP2 induces hyperplasia, dysplasia and low-grade carcinoma in the mouse prostate. Cancer Res 63:1583-1588, 2003
46. Laiho M, Saksela O, Andreasen PA, et al: Enhanced production and extracellular deposition of the endothelial-type plasminogen activator inhibitor in cultured human lung fibroblasts by transforming growth factor-β. J Cell Biol 103:2403-2410, 1986
47. Zambetti DR, Levine AJ: A comparison of the biological activities of wild-type and mutant p53. FASEB J 7:855-865, 1993
48. Navone NM, Troncoso P, Psiters LL, et al: p53 protein accumulation and gene mutation in the progression of human prostate carcinoma. J Natl Cancer Inst 85:1657-1659, 1993
49. Myers RB, Oelschlager D, Srivastava S: Accumulation of the p53 protein occurs more frequently in metastatic than in localized prostatic adenocarcinomas. Prostate 25:243-248, 1998
50. Tamboli P, Amin MB, Xu HJ: Immunohistochemical expression of retinoblastoma and p53 tumor-suppressor genes in prostatic intraepithelial neoplasia: Comparison with prostate adenocarcinoma and benign prostate. Mod Pathol 11:247-252, 1998